$OCUL
first mention in our archive Dec 19, 2025 · latest 2mo ago
Mention stats
16
Mentions (12mo)
1
Voices mentioning
Price · Mention timeline
16 mentions since Dec 2025Loading price chart…
@toplvl_excutive @houmanhemmati Agreed. As I said earlier, $OCUL modeled Axpaxli durability very well, but not so with low dose Eylea. The risk of this unconventional study design may not pay off.
$OCUL was -35% but now recovering a bit -22%.
$OCUL insta-take: Bulls and bears both have something to chew on, highlight. Axpaxli durability almost exactly what $OCUL predicted, but they guessed wrong on Eylea. Fluid control data favors Axpaxli. BCVA doesn't, but TBD with more data disclosure. Investor reaction vs retinal specialist reaction next thing to pay attention to.
$OCUL SOL-1 readout is here! Top-line results: Rescue-free rates: Axpaxli 74% at nine months, 66% at one year vs Eylea low dose 56% and 44%. Difference (benefit) 18 percentage points, 22 percentage points. Stat sig at both time points. This is a narrower durability benefit than expected. Eylea outperformed. Fluid control rate: 56% of participants treated with Axpaxli maintained normal fluid control in the blood vessels around the retina at nine months compared to 38% of participants treated with Eylea. Visual acuity BVCA: No significant difference between Axpaxli and Eylea at nine months. More in my story, including comments from Ocular CEO Pravin Dugel. https://t.co/wXw1FdYT1J
@firebutworking $OCUL BCVA data from SOL-1 equally important bc it translates more to how wet AMD is treated.
@NicholasChoupak 100% agree with you. It's a very odd strategy for $EYPT to take. Duker should be cheering for $OCUL, not trash talking.
I received a strongly worded statement from $OCUL “The rumors that are circulating alleging that we have seen the unmasked results from the SOL-1 trial or have knowledge that the trial did not succeed are categorically false." More in the story...
A rival goes after Ocular Therapeutix $OCUL on eve of pivotal readout on eye treatment Eyepoint Pharma $EYPT CEO said to have trash-talked Ocular’s drug at a recent investor conference https://t.co/LSUm4WPWKA
$OCUL earnings posted this morning, plus an Axpaxli SOL-1 trial update. Topline results will be announced in the "second half of February," the company said today. The study will then be presented at the Macula Society mtg Feb 25-28. "To date, the SOL-1 trial results remain masked."
@BiotechPort Can you define $OCUL fail?” No stat sig difference in maintenance of visual acuity at 9 months? Or the benefit is too marginal?
Is there a single person feeding La Lettre fake biotech takeover tips, or is this a group effort? The stock manipulation is brazen. First, we learn all the $ABVX $LLY French Ministry speculation was fake, now today it's $SNY $OCUL The story explains Sanofi's interest in "combination therapies" --> Dextenza + Dupixent? What the f--k? Dextenza is a tiny eye implant, Dupixent is an injectable. What are you combining? The La Lettre story doesn't even mention Axpaxli or the upcoming SOL-1 ph3 study readout. I think $OCUL is interesting and if SOL-1 hits, the company could be sold. In fact, I wrote that in early January given CEO Pravin Dugel's track record selling Iveric to Astellas. But, please, look at how $OCUL traded at the end of Wednesday.
This week's Biotech Scorecard newsletter: Ocular Therapeutix $OCUL faces looming test of a more durable eye treatment. A preview of the Axpaxli SOL-1 clinical trial readout expected in February https://t.co/XTI2wySnbB
